{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:23:23Z","timestamp":1747167803127,"version":"3.40.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.105039","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T22:10:57Z","timestamp":1695679857000},"page":"105039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Corticosteroid-induced low immunoglobulin levels in multiple sclerosis \u2014 A confounding factor"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-3921","authenticated-orcid":false,"given":"Mickael","family":"Bonnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Courtade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Debeugny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105039_bib0001","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105039_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.msard.2023.105039_bib0003","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI107455","article-title":"Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone","volume":"52","author":"Butler","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2023.105039_bib0004","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/rheumatology\/keaa617","article-title":"Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience","volume":"60","author":"Evangelatos","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2023.105039_bib0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03545.x","article-title":"Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities","volume":"151","author":"Gonzalez-Quintela","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2023.105039_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.105039_bib0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105039_bib0008","first-page":"1","article-title":"Immunoglobulin levels may aid in the prediction of treatment response in anti-CD20 treatment of multiple sclerosis","author":"Hoepner","year":"2018","journal-title":"Clin. Transl. Neurosci."},{"key":"10.1016\/j.msard.2023.105039_bib0009","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/pgmj.61.716.523","article-title":"Hypogammaglobulinaemia associated with long term, low dose steroid therapy","volume":"61","author":"Lee","year":"1985","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.msard.2023.105039_bib0010","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1172\/JCI106385","article-title":"The effect of hydrocortisone on immunoglobulin metabolism","volume":"49","author":"Levy","year":"1970","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2023.105039_bib0011","doi-asserted-by":"crossref","first-page":"e13090","DOI":"10.1111\/aji.13090","article-title":"Serum markers of B-cell activation in pregnancy during late gestation, delivery, and the postpartum period","volume":"81","author":"Lima","year":"2019","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.msard.2023.105039_bib0012","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/1352458520937282","article-title":"Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity","volume":"27","author":"Longbrake","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105039_bib0013","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinno","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.105039_bib0014","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.msard.2023.105039_bib0015","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.msard.2023.105039_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ene.12204","article-title":"A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort","volume":"21","author":"Outteryck","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.105039_bib0017","first-page":"18","article-title":"The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs","volume":"63","author":"Rinkardt","year":"1999","journal-title":"Can. J. Vet. Res."},{"key":"10.1016\/j.msard.2023.105039_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2023.105039_bib0019","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105039_bib0020","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3389\/fimmu.2020.01435","article-title":"Case report-secondary antibody deficiency due to endogenous hypercortisolism","volume":"11","author":"Sarcevic","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.105039_bib0021","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1177\/1352458513477229","article-title":"Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients","volume":"19","author":"Selter","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105039_bib0022","article-title":"Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.105039_bib0023","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3389\/fimmu.2018.01590","article-title":"Higher serum immunoglobulin G3 levels may predict the development of multiple sclerosis in individuals with clinically isolated syndrome","volume":"9","author":"Trend","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.105039_bib0024","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.msard.2023.105039_bib0025","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.msard.2023.105039_bib0026","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105039_bib0027","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/pgmj.62.729.657","article-title":"Cushing's syndrome\u2013transitory immune deficiency state?","volume":"62","author":"Wurzburger","year":"1986","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.msard.2023.105039_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:12:31Z","timestamp":1727453551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823005400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"alternative-id":["S2211034823005400"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105039","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroid-induced low immunoglobulin levels in multiple sclerosis \u2014 A confounding factor","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105039"}}